During the COVID-19 pandemic, research on "cytokine storms" has been reinvigorated in the field of infectious disease, but it also has particular relevance to cancer research. Interleukin-6 (IL-6) has emerged as a key component of the immune response to SARS-CoV-2, such that the repurposing of anti-IL-6 therapeutics for COVID-19 is now a major line of investigation, with several ongoing clinical trials. We lay a framework for understanding the role of IL-6 in the context of cancer research and COVID-19 and suggest how lessons learned from cancer research may impact SARS-CoV-2 research and vice versa.
Journal article
2020-11-09T00:00:00+00:00
38
598 - 601
3
Betacoronavirus, COVID-19, Coronavirus Infections, Cytokines, Humans, Inflammation, Neoplasms, Pandemics, Pneumonia, Viral, SARS-CoV-2, Severity of Illness Index